Short-term outcomes by treatment group.
| Variable | Gly-20 | EA-95 | RFD | Total |
| 6 wk | ||||
| WHO pain level | 1.30 ± 0.68 | 1.48 ± 0.65 | 1.28 ± 0.70 | 1.34 ± 0.68 |
| VAS | 5.67 ± 3.03 | 6.15 ± 3.21a | 4.33 ± 2.83a | 5.36 ± 3.80 |
| COMI-back | 6.65 ± 2.83 | 6.64 ± 3.30 | 5.48 ± 2.85 | 6.26 ± 3.00 |
| 6 mo | ||||
| WHO pain level | 1.36 ± 0.78 | 1.52 ± 0.68 | 1.35 ± 0.83 | 1.40 ± 0.76 |
| VAS | 6.64 ± 2.44b | 6.14 ± 3.05 | 4.42 ± 3.18b | 5.77 ± 3.00 |
| COMI-back | 7.43 ± 2.26b | 6.69 ± 3.14 | 5.08 ± 3.45b | 6.44 ± 3.08 |
aP < 0.05: RFD vs. Eth-95.
bP < 0.01: Gly-20 vs. RFD.
COMI-back, Core Outcome Measures Index for the back; EA-95, ethyl alcohol 95%; Gly-20, glycerol 20%; RFD, radiofrequency denervation; VAS, visual analog scale; WHO, World Health Organization.